Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with a single molecular construct. Based in Basel, Switzerland and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient.

Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional mRNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve to date.

Versameb was part of BaseLaunch, the Basel-Area based incubator and accelerator that supports early-stage ventures developing cutting-edge therapeutics.